Credence MedSystems Announces Commercial Supply Agreement with Global Biopharmaceutical Leader

This agreement reinforces Credence’s role as a trusted partner to the pharmaceutical industry in advancing patient care.

MENLO PARK, CA, UNITED STATES, January 7, 2026 /EINPresswire.com/ — Credence MedSystems, an innovator in advanced injectable delivery systems that solve unmet market needs for the pharmaceutical industry, today announced that it has entered into a Commercial Supply Agreement with a global biopharmaceutical company that is a leader in the field of intra-ocular therapy. This collaboration is centered on ensuring patient safety by equipping healthcare professionals with the tools to seamlessly administer medication at the proper dose, delivering therapy with confidence and precision.
Under the terms of the agreement, Credence will develop, manufacture and supply its proprietary ophthalmic injection delivery device for an ophthalmology program within the partner’s extensive pipeline. Credence’s delivery device is for precise, intra-ophthalmic delivery of drugs, designed specifically to address the unique challenges of ocular drug administration. The device combines intuitive usability with precise dosing capabilities, enabling clinicians to deliver treatments accurately and consistently—critical in ophthalmology where even minor deviations can impact patient outcomes.
The design prioritizes dose accuracy, ergonomics and ease of handling, reducing complexity during administration and minimizing the risk of dosing errors and patient pain. By supporting accurate delivery and enhancing clinician confidence, the device helps maintain patient safety while improving the overall treatment experience.
“This partnership reflects our shared commitment to innovation that enables the delivery of therapies while ensuring patient safety,” said John Merhige, Co-CEO of Credence MedSystems. “By combining our expertise in drug delivery with the partner’s leadership in biologic development, manufacturing and commercial distribution channels, we are providing healthcare professionals with the means to deliver ophthalmic therapies safely and effectively.”
Jeff Tillack, Co-CEO of Credence added, “This agreement represents a significant step forward for delivering advanced, patient-centric solutions for injectable therapies worldwide. Scaling activities to commercial manufacturing are in process.”
Credence MedSystems continues to expand its global footprint through strategic partnerships and agreements that leverage the company’s expertise in innovative solutions to complex drug-delivery challenges.

About Credence MedSystems
Credence MedSystems is an innovator of drug delivery systems that solve unmet market needs for the pharmaceutical industry. Credence’s philosophy of Innovation Without Change allows pharma manufacturers to solve challenges in injectable drug delivery while preserving their existing processes, sourcing strategies and preferred primary package components. This approach enhances patient safety, improves usability, and streamlines combination product development. Credence partners with leading pharmaceutical and biotechnology companies worldwide to advance injectable therapies from clinical to commercial stages.
The Companion^® family of syringe systems includes needle-retraction technology, reuse prevention and other critical safety and usability features in a range of barrel sizes including large volume formats with a superior sustainability profile. The Dual Chamber platform offers simplified and safe delivery of complex drug products requiring reconstitution or sequential injection at the time of delivery. The Credence Connect™ Auto-Sensing Injection System incorporates automatic real-time monitoring of critical injection data into a reusable ergonomic finger grip. Credence’s Metered Dosing devices allow precise single- or multi-injections of microliter volumes for ophtha and medical aesthetics.

John Merhige
Credence MedSystems
+1 844-263-3797
info@credencemed.com

Introduction to Credence Drug Delivery Systems

Legal Disclaimer:

EIN Presswire provides this news content “as is” without warranty of any kind. We do not accept any responsibility or liability
for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this
article. If you have any complaints or copyright issues related to this article, kindly contact the author above.